Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q2 FY23 results · Jul–Sep 2022
Tatva Chintan Pharma Chem reported revenue from operations of ₹90.09 crore (down 27.1% from Q2 FY22) and net profit of ₹7.11 crore (down 78.1% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 90.09 | 123.61 | −27.1% | 88.40 | +1.9% |
| Other income | 1.55 | 2.80 | −44.8% | 1.83 | −15.3% |
| Total income | 91.64 | 126.42 | −27.5% | 90.23 | +1.6% |
| Profit before tax | 9.06 | 35.42 | −74.4% | 13.70 | −33.9% |
| Net profit for the period | 7.11 | 32.41 | −78.1% | 9.80 | −27.4% |
| EPS, basic (₹) | 3.21 | 15.02 | −78.6% | 4.42 | −27.4% |
| Net margin (%) | 7.9 | 26.2 | 11.1 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 84.04 | 116.69 | −28.0% | 86.06 | −2.4% |
| Other income | 1.55 | 2.60 | −40.3% | 1.83 | −15.3% |
| Total income | 85.59 | 119.28 | −28.2% | 87.89 | −2.6% |
| Profit before tax | 6.81 | 33.55 | −79.7% | 11.98 | −43.1% |
| Net profit for the period | 5.26 | 30.72 | −82.9% | 8.50 | −38.2% |
| EPS, basic (₹) | 2.37 | 14.24 | −83.4% | 3.83 | −38.1% |
| Net margin (%) | 6.3 | 26.3 | 9.9 |
Consolidated
- Filed with BSE
- 07 Nov 2022, 12:09 IST
- Board meeting
- 04 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2022, 12:09 IST
- Board meeting
- 04 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE